{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:34:16Z","timestamp":1761514456628,"version":"build-2065373602"},"reference-count":88,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2019,11,15]],"date-time":"2019-11-15T00:00:00Z","timestamp":1573776000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>To identify the pharmacokinetic differences of antiretroviral drugs between HIV\u2010infected Chinese patients and patients of other race\/ethnicities.<\/jats:p><\/jats:sec><jats:sec><jats:title>Study Design<\/jats:title><jats:p>Results from prospective, open\u2010label pharmacokinetic studies among Chinese and historical data from other race\/ethnicities.<\/jats:p><\/jats:sec><jats:sec><jats:title>Patients<\/jats:title><jats:p>Pharmacokinetics of six commonly used antiretroviral drugs, including zidovudine, lamivudine, tenofovir disoproxil fumarate, nevirapine, efavirenz and lopinavir\/ritonavir, was evaluated in HIV\u2010infected Chinese patients and compared with historical data from other race\/ethnicities.<\/jats:p><\/jats:sec><jats:sec><jats:title>Analysis<\/jats:title><jats:p>Pharmacokinetic analyses were performed at the steady state among HIV\u2010infected Chinese patients. Safety data were collected during the follow\u2010up. The pharmacokinetic parameters including maximal concentrations (Cmax), area\u2010under\u2010curve (AUC) and clearance (Cl\/F) from the Chinese patients were compared to the historic data from other race\/ethnicities.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Current evidence, though limited, suggested that these antiretroviral agents were generally safe and effective among HIV\u2010infected Chinese patients. However, compared with other racial groups, Chinese patients exhibited higher <jats:italic>C<\/jats:italic><jats:sub>max<\/jats:sub>, AUC and lower Cl\/F for most of the agents, and the incidences of adverse reactions, for example, liver toxicity, rash, and bone health, were more frequent.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>These pharmacokinetic differences suggest that lower dosages for commonly prescribed antiretroviral drugs in China might be appropriate to reduce drug\u2010related adverse reactions, while maintain the antiviral efficacy.<\/jats:p><\/jats:sec>","DOI":"10.1002\/phar.2333","type":"journal-article","created":{"date-parts":[[2019,9,24]],"date-time":"2019-09-24T11:18:29Z","timestamp":1569323909000},"page":"1179-1189","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["A Review of Clinical Pharmacokinetic and Pharmacodynamic Profiles of Select Antiretrovirals: Focus on Differences among Chinese Patients"],"prefix":"10.1002","volume":"39","author":[{"given":"Xiaoli","family":"Du","sequence":"first","affiliation":[{"name":"Department of Pharmacy Peking Union Medical College Hospital Chinese Academy of Medical Sciences Beijing China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0308-6279","authenticated-orcid":false,"given":"Wenxiu","family":"Peng","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Peking Union Medical College Hospital Chinese Academy of Medical Sciences Beijing China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiang","family":"Fu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Peking Union Medical College Hospital Chinese Academy of Medical Sciences Beijing China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0123-9913","authenticated-orcid":false,"given":"Qing","family":"Ma","sequence":"additional","affiliation":[{"name":"Translational Pharmacology Research Core NYS Center of Excellence in Bioinformatics and Life Sciences Buffalo New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhu","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Peking Union Medical College Hospital Chinese Academy of Medical Sciences Beijing China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taisheng","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases AIDS Diagnosis and Treatment Center Peking Union Medical College Hospital Chinese Academy of Medical Sciences Beijing China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2019,11,15]]},"reference":[{"unstructured":"Food and Drug Administration.Antiretroviral drugs used in the treatment of HIV infection.2018. Available fromhttps:\/\/www.fda.gov\/patients\/hiv-treatment\/antiretroviral-drugs-used-treatment-hiv-infection. Accessed May 14 2018.","key":"e_1_2_7_2_1"},{"doi-asserted-by":"publisher","key":"e_1_2_7_3_1","DOI":"10.1016\/S0140-6736(98)03201-2"},{"doi-asserted-by":"publisher","key":"e_1_2_7_4_1","DOI":"10.7326\/0003-4819-135-1-200107030-00005"},{"doi-asserted-by":"publisher","key":"e_1_2_7_5_1","DOI":"10.1001\/jama.2016.8900"},{"unstructured":"World Health Organization.Update of recommendations on first\u2010 and second\u2010line antiretroviral regimens.2019. Available fromhttps:\/\/www.who.int\/hiv\/en\/. Accessed September 7 2019.","key":"e_1_2_7_6_1"},{"doi-asserted-by":"publisher","key":"e_1_2_7_7_1","DOI":"10.1097\/00029330-200610020-00002"},{"doi-asserted-by":"publisher","key":"e_1_2_7_8_1","DOI":"10.1371\/journal.pone.0003918"},{"doi-asserted-by":"publisher","key":"e_1_2_7_9_1","DOI":"10.1097\/QAI.0b013e3181cc5964"},{"doi-asserted-by":"publisher","key":"e_1_2_7_10_1","DOI":"10.1310\/hct1104-230"},{"doi-asserted-by":"publisher","key":"e_1_2_7_11_1","DOI":"10.1371\/journal.pone.0026739"},{"key":"e_1_2_7_12_1","first-page":"1931","article-title":"Steady\u2010state pharmacokinetics of zidovudine in Chinese HIV\u2010infected patients","volume":"11","author":"Liu L","year":"2012","journal-title":"Natl Med J China"},{"doi-asserted-by":"publisher","key":"e_1_2_7_13_1","DOI":"10.1186\/1471-2334-13-301"},{"doi-asserted-by":"publisher","key":"e_1_2_7_14_1","DOI":"10.1371\/journal.pone.0052950"},{"key":"e_1_2_7_15_1","doi-asserted-by":"crossref","first-page":"e0120705","DOI":"10.1371\/journal.pone.0120705","article-title":"Week 120 efficacy of tenofovir, lamivudine and lopinavir\/r\u2010based second\u2010line antiretroviral therapy in treatment\u2010experienced HIV patients","volume":"3","author":"Han Y","year":"2015","journal-title":"PLoS One"},{"doi-asserted-by":"publisher","key":"e_1_2_7_16_1","DOI":"10.1007\/s00198-014-2874-3"},{"key":"e_1_2_7_17_1","first-page":"431","article-title":"Pharmacokinetic profiles of lopinavir (LPV) in Chinese HIV\u2010infected patients.","volume":"5","author":"Zhang X","year":"2015","journal-title":"Chin J Intern Med"},{"doi-asserted-by":"publisher","key":"e_1_2_7_18_1","DOI":"10.1080\/17512433.2017.1321480"},{"key":"e_1_2_7_19_1","first-page":"1","volume-title":"Studies on the pharmacokinetics and pharmacodynamics of drugs used for HAART in Chinese patients","author":"Wang L","year":"2008"},{"key":"e_1_2_7_20_1","first-page":"1","volume-title":"Study on pharmacodynamics and pharmacokinetics of three antiretroviral drugs in Chinese patients with HIV infection","author":"Huijuan K","year":"2012"},{"key":"e_1_2_7_21_1","first-page":"1","volume-title":"Analysis of efavirenz plasma levels in Chinese HIV\/AIDS patients treated with HAART","author":"Xin C","year":"2016"},{"doi-asserted-by":"publisher","key":"e_1_2_7_22_1","DOI":"10.1128\/AAC.45.1.236-242.2001"},{"doi-asserted-by":"publisher","key":"e_1_2_7_23_1","DOI":"10.1128\/AAC.41.11.2428"},{"doi-asserted-by":"publisher","key":"e_1_2_7_24_1","DOI":"10.1128\/AAC.39.6.1355"},{"doi-asserted-by":"publisher","key":"e_1_2_7_25_1","DOI":"10.1128\/AAC.35.11.2225"},{"doi-asserted-by":"publisher","key":"e_1_2_7_26_1","DOI":"10.1592\/phco.21.5.424.34497"},{"doi-asserted-by":"publisher","key":"e_1_2_7_27_1","DOI":"10.1128\/AAC.44.8.2061-2067.2000"},{"doi-asserted-by":"publisher","key":"e_1_2_7_28_1","DOI":"10.1128\/AAC.43.7.1708"},{"doi-asserted-by":"publisher","key":"e_1_2_7_29_1","DOI":"10.1016\/S1550-8579(07)80025-8"},{"doi-asserted-by":"publisher","key":"e_1_2_7_30_1","DOI":"10.1097\/00002030-199412000-00007"},{"doi-asserted-by":"publisher","key":"e_1_2_7_31_1","DOI":"10.1097\/00002030-200310170-00003"},{"doi-asserted-by":"publisher","key":"e_1_2_7_32_1","DOI":"10.1086\/424009"},{"doi-asserted-by":"publisher","key":"e_1_2_7_33_1","DOI":"10.1056\/NEJM199010113231502"},{"doi-asserted-by":"publisher","key":"e_1_2_7_34_1","DOI":"10.1056\/NEJM199010113231501"},{"key":"e_1_2_7_35_1","first-page":"13","article-title":"Double blind dose\u2010response study of zidovudine in AIDS and advanced HIV infection. Nordic Medical Research Councils' HIV Therapy Group","volume":"6818","author":"Listed N","year":"1992","journal-title":"BMJ"},{"doi-asserted-by":"publisher","key":"e_1_2_7_36_1","DOI":"10.1128\/AAC.38.8.1726"},{"doi-asserted-by":"publisher","key":"e_1_2_7_37_1","DOI":"10.1097\/QAI.0b013e3181bc0f10"},{"doi-asserted-by":"publisher","key":"e_1_2_7_38_1","DOI":"10.1097\/01.qai.0000221685.90681.1b"},{"doi-asserted-by":"publisher","key":"e_1_2_7_39_1","DOI":"10.2337\/dc07-2013"},{"doi-asserted-by":"publisher","key":"e_1_2_7_40_1","DOI":"10.1097\/QAI.0b013e31815e7453"},{"doi-asserted-by":"publisher","key":"e_1_2_7_41_1","DOI":"10.1186\/1476-511X-12-50"},{"doi-asserted-by":"publisher","key":"e_1_2_7_42_1","DOI":"10.1177\/2325957415614642"},{"doi-asserted-by":"publisher","key":"e_1_2_7_43_1","DOI":"10.2165\/00003088-200140090-00005"},{"key":"e_1_2_7_44_1","first-page":"176","article-title":"Equivalent steady\u2010state pharmacokinetics of lamivudine in plasma and lamivudine triphosphate within cells following administration of lamivudine at 300 milligrams once daily and 150 milligrams twice daily","volume":"1","author":"Yuen GJ","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"doi-asserted-by":"publisher","key":"e_1_2_7_45_1","DOI":"10.2165\/00003088-200443090-00003"},{"doi-asserted-by":"publisher","key":"e_1_2_7_46_1","DOI":"10.1089\/aid.2014.0249"},{"key":"e_1_2_7_47_1","first-page":"105980","article-title":"Effect of food on the steady\u2010state pharmacokinetics of tenofovir and emtricitabine plus efavirenz in Ugandan adults","volume":"10","author":"Lamorde M","year":"2012","journal-title":"AIDS Res Treat"},{"doi-asserted-by":"publisher","key":"e_1_2_7_48_1","DOI":"10.1128\/AAC.00761-07"},{"doi-asserted-by":"publisher","key":"e_1_2_7_49_1","DOI":"10.1128\/AAC.01064-08"},{"doi-asserted-by":"publisher","key":"e_1_2_7_50_1","DOI":"10.1016\/j.clinthera.2013.09.020"},{"doi-asserted-by":"publisher","key":"e_1_2_7_51_1","DOI":"10.1128\/AAC.50.4.1304-1310.2006"},{"doi-asserted-by":"publisher","key":"e_1_2_7_52_1","DOI":"10.1097\/01.qai.0000243103.03265.2b"},{"doi-asserted-by":"publisher","key":"e_1_2_7_53_1","DOI":"10.1111\/j.1468-1293.2008.00668.x"},{"doi-asserted-by":"publisher","key":"e_1_2_7_54_1","DOI":"10.1371\/journal.pone.0080242"},{"doi-asserted-by":"publisher","key":"e_1_2_7_55_1","DOI":"10.1097\/QAI.0b013e31815e7478"},{"doi-asserted-by":"publisher","key":"e_1_2_7_56_1","DOI":"10.1097\/QAD.0000000000000033"},{"doi-asserted-by":"publisher","key":"e_1_2_7_57_1","DOI":"10.7448\/IAS.17.4.19583"},{"doi-asserted-by":"publisher","key":"e_1_2_7_58_1","DOI":"10.1097\/00002030-200106150-00003"},{"doi-asserted-by":"publisher","key":"e_1_2_7_59_1","DOI":"10.1097\/00002030-200101050-00011"},{"key":"e_1_2_7_60_1","first-page":"1","article-title":"Non\u2010nucleoside reverse transcriptase inhibitors: a review on pharmacokinetics, pharmacodynamics, safety and tolerability","volume":"1","author":"Usach I","year":"2013","journal-title":"J Int AIDS Soc"},{"doi-asserted-by":"publisher","key":"e_1_2_7_61_1","DOI":"10.2165\/00003088-200342060-00009"},{"doi-asserted-by":"publisher","key":"e_1_2_7_62_1","DOI":"10.1111\/j.1365-2125.2006.02664.x"},{"doi-asserted-by":"publisher","key":"e_1_2_7_63_1","DOI":"10.1177\/1545109707301344"},{"doi-asserted-by":"publisher","key":"e_1_2_7_64_1","DOI":"10.1111\/j.1365-2125.2009.03430.x"},{"doi-asserted-by":"publisher","key":"e_1_2_7_65_1","DOI":"10.1093\/jac\/dkp044"},{"doi-asserted-by":"publisher","key":"e_1_2_7_66_1","DOI":"10.1093\/jac\/dks207"},{"doi-asserted-by":"publisher","key":"e_1_2_7_67_1","DOI":"10.5588\/ijtld.12.0427"},{"key":"e_1_2_7_68_1","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1177\/135965350801300507","article-title":"Factors influencing efavirenz and nevirapine plasma concentration: effect of ethnicity, weight and co\u2010medication","volume":"5","author":"St\u00f6hr W","year":"2008","journal-title":"Antivir Ther"},{"doi-asserted-by":"publisher","key":"e_1_2_7_69_1","DOI":"10.1128\/AAC.49.8.3558-3561.2005"},{"doi-asserted-by":"publisher","key":"e_1_2_7_70_1","DOI":"10.1111\/j.1468-1293.2004.00194.x"},{"unstructured":"ManionDJ.DMP 266\u2013021: A phase II open label study to assess the pharmacokinetic profile of DMP 266 dosed at bedtime in combination with Indinavir in HIV\u2010Infected Patients. Clinical Study Report. Wilmington DE: The Dupont Merck Pharmaceutical Company 1998.","key":"e_1_2_7_71_1"},{"key":"e_1_2_7_72_1","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1046\/j.1365-2125.1999.00071.x","article-title":"Pharmacokinetics of efavirenz (EFV) alone and in combination therapy with nelfinavir (NFV) in HIV\u20101 infected patients","volume":"5","author":"Villani P","year":"1999","journal-title":"Br J Clin Pharmacol"},{"doi-asserted-by":"publisher","key":"e_1_2_7_73_1","DOI":"10.1086\/320998"},{"doi-asserted-by":"publisher","key":"e_1_2_7_74_1","DOI":"10.1038\/tpj.2011.34"},{"doi-asserted-by":"publisher","key":"e_1_2_7_75_1","DOI":"10.1086\/497835"},{"key":"e_1_2_7_76_1","doi-asserted-by":"crossref","first-page":"e0130583","DOI":"10.1371\/journal.pone.0130583","article-title":"Effect of CYP2B6 gene polymorphisms on efavirenz plasma concentrations in Chinese patients with HIV infection","volume":"6","author":"Meng X","year":"2015","journal-title":"PLoS One"},{"doi-asserted-by":"publisher","key":"e_1_2_7_77_1","DOI":"10.1007\/s40262-015-0360-5"},{"doi-asserted-by":"publisher","key":"e_1_2_7_78_1","DOI":"10.1002\/cpt.156"},{"doi-asserted-by":"publisher","key":"e_1_2_7_79_1","DOI":"10.1586\/14787210.1.3.389"},{"doi-asserted-by":"publisher","key":"e_1_2_7_80_1","DOI":"10.1517\/14740338.4.3.403"},{"doi-asserted-by":"publisher","key":"e_1_2_7_81_1","DOI":"10.3109\/00498254.2016.1166532"},{"doi-asserted-by":"publisher","key":"e_1_2_7_82_1","DOI":"10.1086\/380799"},{"doi-asserted-by":"publisher","key":"e_1_2_7_83_1","DOI":"10.1097\/FTD.0b013e3182a28c6a"},{"doi-asserted-by":"publisher","key":"e_1_2_7_84_1","DOI":"10.1093\/jac\/dkr490"},{"doi-asserted-by":"publisher","key":"e_1_2_7_85_1","DOI":"10.1097\/FTD.0b013e318177209e"},{"doi-asserted-by":"publisher","key":"e_1_2_7_86_1","DOI":"10.5588\/ijtld.15.0044"},{"key":"e_1_2_7_87_1","first-page":"293","article-title":"Life expectancy of individuals on combination antiretroviral therapy in high\u2010income countries: a collaborative analysis of 14 cohort studies","volume":"9635","author":"Antiretroviral Therapy Cohort Collaboration","year":"2008","journal-title":"Lancet"},{"key":"e_1_2_7_88_1","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1177\/135965350801300507","article-title":"Factors influencing efavirenz and nevirapine plasma concentration: effect of ethnicity, weight and co\u2010medication","volume":"5","author":"Stohr W","year":"2008","journal-title":"Antivir Ther"},{"doi-asserted-by":"publisher","key":"e_1_2_7_89_1","DOI":"10.4103\/0366-6999.174509"}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fphar.2333","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/phar.2333","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/phar.2333","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/phar.2333","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T14:21:48Z","timestamp":1761056508000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1002\/phar.2333"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,15]]},"references-count":88,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["10.1002\/phar.2333"],"URL":"https:\/\/doi.org\/10.1002\/phar.2333","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"type":"print","value":"0277-0008"},{"type":"electronic","value":"1875-9114"}],"subject":[],"published":{"date-parts":[[2019,11,15]]},"assertion":[{"value":"2019-11-15","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}